跳至主要内容
临床试验/JPRN-UMIN000018292
JPRN-UMIN000018292已完成未知

The efficacy and safety of Tadarafil for treatment of nocturia and sleep quality - The efficacy of Tadarafil for nocturia and sleep disturbance

Fujita Health University0 个研究点目标入组 50 人开始时间: 2015年7月13日最近更新:

试验速览

阶段
未知
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
40years-old 至 ot applicable(—)
性别
Male

入选标准

  • 未提供

排除标准

  • 1.Patients with a history of hypersensitivity to components of this drug 2.Patients with a history of serious cardiovascular (It have been reported heart rate increases, and there is a risk that symptoms worse. 3.Patients with severe hypertension 4.Patients with severe liver dysfunction (Child-Pugh score 10 or more) [There is a possibility that the blood concentration is excessively increased.] 5.Patients treated with flecainide acetate or propafenone hydrochloride in administration 6.Patients with chronic bacterial prostatitis or activity of urinary tract infection 7.Patients who carried the radiation therapy to the pelvis 8.Patients who suspected of having prostate cancer by PSA or rectal examination 9.Patients with urethral stricture 10.Patients who are considered ineligible for the study by the attending physician

研究者

相似试验